490 related articles for article (PubMed ID: 26353041)
1. Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?
Gibney GT; Atkins MB
Clin Adv Hematol Oncol; 2015 Jul; 13(7):451-8. PubMed ID: 26353041
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.
Atkins MB; Tarhini A; Rael M; Gupte-Singh K; O'Brien E; Ritchings C; Rao S; McDermott DF
Immunotherapy; 2019 May; 11(7):617-629. PubMed ID: 30852924
[TBL] [Abstract][Full Text] [Related]
3. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
4. The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era.
Vanella V; Festino L; Trojaniello C; Vitale MG; Sorrentino A; Paone M; Ascierto PA
Curr Oncol Rep; 2019 Jul; 21(9):76. PubMed ID: 31359162
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma.
Luke JJ
Oncologist; 2019 Nov; 24(11):e1197-e1211. PubMed ID: 31064886
[TBL] [Abstract][Full Text] [Related]
6. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
[TBL] [Abstract][Full Text] [Related]
7. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
8. Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era.
Wood K; Luke JJ
Curr Oncol Rep; 2016 Nov; 18(11):67. PubMed ID: 27613168
[TBL] [Abstract][Full Text] [Related]
9. Gaining momentum: New options and opportunities for the treatment of advanced melanoma.
Michielin O; Hoeller C
Cancer Treat Rev; 2015 Sep; 41(8):660-70. PubMed ID: 26096079
[TBL] [Abstract][Full Text] [Related]
10. BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.
Queirolo P; Spagnolo F
Cancer Metastasis Rev; 2017 Mar; 36(1):35-42. PubMed ID: 28299583
[TBL] [Abstract][Full Text] [Related]
11. Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study.
Luke JJ; Ghate SR; Kish J; Lee CH; McAllister L; Mehta S; Ndife B; Feinberg BA
Future Oncol; 2019 Sep; 15(25):2933-2942. PubMed ID: 30799646
[No Abstract] [Full Text] [Related]
12. Current and future roles of targeted therapy and immunotherapy in advanced melanoma.
Olszanski AJ
J Manag Care Spec Pharm; 2014 Apr; 20(4):346-56. PubMed ID: 24684639
[TBL] [Abstract][Full Text] [Related]
13. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.
King JW; Nathan PD
Future Oncol; 2014; 10(9):1559-70. PubMed ID: 25145427
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapy for Melanoma.
Wong DJ; Ribas A
Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
[TBL] [Abstract][Full Text] [Related]
15. Integrating first-line treatment options into clinical practice: what's new in advanced melanoma?
Dummer R; Schadendorf D; Ascierto PA; Larkin J; Lebbé C; Hauschild A
Melanoma Res; 2015 Dec; 25(6):461-9. PubMed ID: 26426764
[TBL] [Abstract][Full Text] [Related]
16. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
Queirolo P; Picasso V; Spagnolo F
Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
[TBL] [Abstract][Full Text] [Related]
17. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
18. Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma.
Aya F; Fernandez-Martinez A; Gaba L; Victoria I; Tosca M; Pineda E; Gascon P; Prat A; Arance A
Clin Transl Oncol; 2017 Jan; 19(1):119-124. PubMed ID: 27147251
[TBL] [Abstract][Full Text] [Related]
19. BRAF and MEK inhibition in melanoma.
Dossett LA; Kudchadkar RR; Zager JS
Expert Opin Drug Saf; 2015 Apr; 14(4):559-70. PubMed ID: 25648338
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous Complications of Targeted Melanoma Therapy.
de Golian E; Kwong BY; Swetter SM; Pugliese SB
Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
